BR112018073741A2 - composição imunogênica, método para imunizar um mamífero contra a malária, e, molécula de ácido nucleico. - Google Patents

composição imunogênica, método para imunizar um mamífero contra a malária, e, molécula de ácido nucleico.

Info

Publication number
BR112018073741A2
BR112018073741A2 BR112018073741-0A BR112018073741A BR112018073741A2 BR 112018073741 A2 BR112018073741 A2 BR 112018073741A2 BR 112018073741 A BR112018073741 A BR 112018073741A BR 112018073741 A2 BR112018073741 A2 BR 112018073741A2
Authority
BR
Brazil
Prior art keywords
immunizing
nucleic acid
acid molecule
against malaria
immunogenic composition
Prior art date
Application number
BR112018073741-0A
Other languages
English (en)
Inventor
B. Weiner David
Reuschel Emma
Ferraro Bernadette
S.I. Aly Ahmed
Original Assignee
The Trustees Of The University Of Pennsylvania
The Wistar Institute Of Anatomy And Biology
Inovio Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Trustees Of The University Of Pennsylvania, The Wistar Institute Of Anatomy And Biology, Inovio Pharmaceuticals, Inc. filed Critical The Trustees Of The University Of Pennsylvania
Publication of BR112018073741A2 publication Critical patent/BR112018073741A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

são fornecidas neste documento sequências de proteínas em fase hepática de plasmodium spp., bem como os construtos de expressam que expressam as sequências. também são fornecidos neste documento métodos para gerar uma resposta imune contra a malária usando os construtos de expressão fornecidos neste documento.
BR112018073741-0A 2016-05-19 2017-05-19 composição imunogênica, método para imunizar um mamífero contra a malária, e, molécula de ácido nucleico. BR112018073741A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662338841P 2016-05-19 2016-05-19
US62/338841 2016-05-19
PCT/US2017/033617 WO2017201454A1 (en) 2016-05-19 2017-05-19 Synthetic malaria immunogens, combinations thereof, and their use to prevent and treat malaria infections

Publications (1)

Publication Number Publication Date
BR112018073741A2 true BR112018073741A2 (pt) 2019-04-09

Family

ID=60325662

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018073741-0A BR112018073741A2 (pt) 2016-05-19 2017-05-19 composição imunogênica, método para imunizar um mamífero contra a malária, e, molécula de ácido nucleico.

Country Status (9)

Country Link
US (1) US20190307870A1 (pt)
EP (1) EP3458086A4 (pt)
JP (1) JP2019516741A (pt)
KR (1) KR20190044587A (pt)
AU (1) AU2017268453A1 (pt)
BR (1) BR112018073741A2 (pt)
CA (1) CA3024950A1 (pt)
MX (1) MX2018014253A (pt)
WO (1) WO2017201454A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020014013A1 (en) * 2018-07-09 2020-01-16 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Viral-vectored vaccine for malaria

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5814617A (en) * 1994-10-07 1998-09-29 The United States Of America As Represented By The Secretary Of The Navy Protective 17 KDA malaria hepatic and erythrocytic stage immunogen and gene
EP1544211A1 (en) * 2003-12-15 2005-06-22 Institut Pasteur LSA-5 pre-erythrocytic stage antigen of plasmodium falciparum, immunogenic composition comprising said antigen, and vaccines against malaria
US20110229514A1 (en) * 2009-03-16 2011-09-22 Denise Doolan Vaccine and immunization method using plasmodium antigen 2
EP2385107B1 (en) * 2010-05-03 2016-08-24 Institut Pasteur Lentiviral vector based immunological compounds against malaria
US20140348870A1 (en) * 2011-11-30 2014-11-27 The Regents Of The University Of California Immunogenic plasmodium falciparum antigen compositions and uses thereof
GB201318084D0 (en) * 2013-10-11 2013-11-27 Isis Innovation Malaria vaccination

Also Published As

Publication number Publication date
US20190307870A1 (en) 2019-10-10
JP2019516741A (ja) 2019-06-20
EP3458086A4 (en) 2020-07-29
AU2017268453A8 (en) 2020-06-04
MX2018014253A (es) 2019-11-11
WO2017201454A1 (en) 2017-11-23
EP3458086A1 (en) 2019-03-27
AU2017268453A1 (en) 2019-01-17
CA3024950A1 (en) 2017-11-23
KR20190044587A (ko) 2019-04-30

Similar Documents

Publication Publication Date Title
CY1125029T1 (el) Τροποποιημενοι νουκλεοζιτες, νουκλεοτιδια, και νουκλεϊκα οξεα και χρησεις αυτων
CO2017011957A2 (es) Variantes de alfa-amilasa y polinucleótidos que codifican las mismas
CO2017013398A2 (es) Anticuerpos anti-ctla-4
CO2017001573A2 (es) Receptor quimérico de antígeno anti-cd123
CO2017000510A2 (es) Constructos de car
MX2022013540A (es) Constructos de expresion y metodos para dise?ar geneticamente levadura metilotrofica.
CO2017000506A2 (es) Receptor quimérico de antígeno cll-1
UY37523A (es) Anticuerpos anti-ox40 y sus usos
PE20210107A1 (es) Anticuerpos anti-cd3 y metodos de uso
AR103225A1 (es) Composiciones detergentes, variantes de lipasa y polinucleótidos que las codifican
EA201691374A1 (ru) Инсулин длительного действия и его применение
BR112015021753A2 (pt) promotores de levedura provenientes de pichia pastoris
CL2018002493A1 (es) Péptidos, ácidos nucleicos, vectores de expresión y células para la utilización en inmunoterapia contra el cáncer. (divisional solicitud 201600227)
MX2023009421A (es) Construcciones de anticuerpos de adn y metodo para utilizarlas.
CY1120997T1 (el) Πρωτεϊνες συντηξης uti
UY36617A (es) Proteínas de fusión inmunogénicas para el tratamiento del cáncer
BR112019001115A2 (pt) proteínas de biofusão como vacinas anti-malária
BR112019005516A2 (pt) novo sítio de inserção do ehv orf70
CL2020001137A1 (es) Anticuerpos anti-apoc3 y métodos de uso de estos.
ZA201603187B (en) Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors
CL2019000705A1 (es) Nuevos promotores.
DK3389701T3 (da) Nucleotidesekvens, der udtrykker et exosomforankrende, protein til anvendelse som vaccine
CR20130662A (es) Anticuerpos a adp-ribosil ciclasa 2
BR112018073741A2 (pt) composição imunogênica, método para imunizar um mamífero contra a malária, e, molécula de ácido nucleico.
BR112018005464A2 (pt) expressão de proteínas contendo fc

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]